Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
1 recherche sur le mot-clé 'Dyslipidemia'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Systematic review investigating the relationship between autism spectrum disorder and metabolic dysfunction / Angela Y. CHIEH in Research in Autism Spectrum Disorders, 86 (August 2021)
[article]
Titre : Systematic review investigating the relationship between autism spectrum disorder and metabolic dysfunction Type de document : Texte imprimé et/ou numérique Auteurs : Angela Y. CHIEH, Auteur ; Bianca M. BRYANT, Auteur ; Jung Won KIM, Auteur ; Li LI, Auteur Article en page(s) : 101821 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder Metabolic dysfunction Metabolic syndrome Type 2 diabetes Hypertension Dyslipidemia Index. décimale : PER Périodiques Résumé : The objective of this systematic review is to examine metabolic dysfunction, specifically metabolic syndrome and its components, as well as type 2 diabetes mellitus (T2DM) as it relates to individuals with a diagnosis of Autism Spectrum Disorder (ASD). We searched PubMed, Embase, Cochrane, PsychInfo, and Scopus from January 1, 1998 to October 12, 2018 for English, peer-reviewed, original articles containing adult and pediatric populations with any form of ASD and metabolic dysfunction, including T2DM, hyperglycemia, hypertension, dyslipidemia, or central obesity. Exclusion criteria included studies without ASD-specific results, basic science research, review papers, case studies, and medication clinical trials. Eight studies were included in this review, with a total of 70,503 participants with ASD and 2,281,891 in comparison groups. Within ASD populations, higher prevalence for metabolic syndrome components hyperglycemia, hypertension, and dyslipidemia were observed, as well as increased incidence and prevalence of T2DM. However, heterogeneity of study definitions and measurements should be noted. While there is evidence of increased prevalence of T2DM, hyperglycemia, hypertension, and dyslipidemia for those with ASD, the relationship is poorly understood. There is also lack of research investigating central obesity and risk of metabolic syndrome as a diagnosis. More research addressing these gaps is warranted to evaluate the risk of metabolic dysfunction in populations with ASD. En ligne : https://doi.org/10.1016/j.rasd.2021.101821 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=458
in Research in Autism Spectrum Disorders > 86 (August 2021) . - 101821[article] Systematic review investigating the relationship between autism spectrum disorder and metabolic dysfunction [Texte imprimé et/ou numérique] / Angela Y. CHIEH, Auteur ; Bianca M. BRYANT, Auteur ; Jung Won KIM, Auteur ; Li LI, Auteur . - 101821.
Langues : Anglais (eng)
in Research in Autism Spectrum Disorders > 86 (August 2021) . - 101821
Mots-clés : Autism spectrum disorder Metabolic dysfunction Metabolic syndrome Type 2 diabetes Hypertension Dyslipidemia Index. décimale : PER Périodiques Résumé : The objective of this systematic review is to examine metabolic dysfunction, specifically metabolic syndrome and its components, as well as type 2 diabetes mellitus (T2DM) as it relates to individuals with a diagnosis of Autism Spectrum Disorder (ASD). We searched PubMed, Embase, Cochrane, PsychInfo, and Scopus from January 1, 1998 to October 12, 2018 for English, peer-reviewed, original articles containing adult and pediatric populations with any form of ASD and metabolic dysfunction, including T2DM, hyperglycemia, hypertension, dyslipidemia, or central obesity. Exclusion criteria included studies without ASD-specific results, basic science research, review papers, case studies, and medication clinical trials. Eight studies were included in this review, with a total of 70,503 participants with ASD and 2,281,891 in comparison groups. Within ASD populations, higher prevalence for metabolic syndrome components hyperglycemia, hypertension, and dyslipidemia were observed, as well as increased incidence and prevalence of T2DM. However, heterogeneity of study definitions and measurements should be noted. While there is evidence of increased prevalence of T2DM, hyperglycemia, hypertension, and dyslipidemia for those with ASD, the relationship is poorly understood. There is also lack of research investigating central obesity and risk of metabolic syndrome as a diagnosis. More research addressing these gaps is warranted to evaluate the risk of metabolic dysfunction in populations with ASD. En ligne : https://doi.org/10.1016/j.rasd.2021.101821 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=458